Open AccessOverall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review)
Author(s) -
Ashok Vaid,
Alok Gupta,
Gagandeep Momi
Publication year - 2021
Publication title -
international journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.405
H-Index - 122
ISSN - 1019-6439
DOI - 10.3892/ijo.2021.5168
Subject(s) - osimertinib , medicine , oncology , lung cancer , clinical endpoint , hazard ratio , gefitinib , epidermal growth factor receptor , progression free survival , confidence interval , cancer , erlotinib , clinical trial , chemotherapy